Roche Holding AG
SIX:ROG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vector Capital PLC
LSE:VCAP
|
UK |
|
WH Ireland Group PLC
LSE:WHI
|
UK |
|
Danske Andelskassers Bank A/S
CSE:DAB
|
DK |
|
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
|
US |
|
F
|
Future PLC
F:FNWA
|
UK |
|
W
|
Whitehaven Coal Ltd
SWB:WC2
|
AU |
|
D
|
Daihen Corp
TSE:6622
|
JP |
|
Rajoo Engineers Ltd
BSE:522257
|
IN |
|
C
|
Cheetah Oil & Gas Ltd
OTC:COHG
|
CA |
|
ALK-Abello A/S
F:4AJ0
|
DK |
|
Companhia de Saneamento Basico do Estado de Sao Paulo SABESP
NYSE:SBS
|
BR |
|
GYM Group PLC
LSE:GYM
|
UK |
|
Shandong Intco Recycling Resources Co Ltd
SSE:688087
|
CN |
|
Mitra Investindo Tbk PT
IDX:MITI
|
ID |
|
M
|
Maxar Technologies Inc
TSX:MAXR
|
US |
|
KCP Ltd
NSE:KCP
|
IN |
|
T
|
Thu Duc Water Supply JSC
VN:TDW
|
VN |
|
USS Co Ltd
TSE:4732
|
JP |
|
Lucibel SA
PAR:ALUCI
|
FR |
|
U
|
Unique Fire Holdings Bhd
KLSE:UNIQUE
|
MY |
|
G
|
GOME Retail Holdings Ltd
SWB:CKS2
|
HK |
|
Pacific Biosciences of California Inc
NASDAQ:PACB
|
US |
|
MedPeer Inc
TSE:6095
|
JP |
|
H
|
H+H International A/S
CSE:HH
|
DK |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
588.6B USD |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.7B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
231.9B CHF |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.6B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
159.7B USD |
Loading...
|
|
| DE |
|
Bayer AG
XETRA:BAYN
|
39.4B EUR |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
233B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK |
Loading...
|
Market Distribution
| Min | -62 472.2% |
| 30th Percentile | 3.5% |
| Median | 10.3% |
| 70th Percentile | 16.5% |
| Max | 91.2% |
Other Profitability Ratios
Roche Holding AG
Glance View
Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Roche Holding AG is 35%, which is above its 3-year median of 32.8%.
Over the last 3 years, Roche Holding AG’s Operating Margin has increased from 31.5% to 35%. During this period, it reached a low of 31.2% on Jun 30, 2023 and a high of 35% on Jan 1, 2026.